BioCentury
ARTICLE | Clinical News

Kevetrin: Ph IIa started

February 16, 2017 8:22 PM UTC

Cellceutix began an open-label, U.S. Phase IIa trial to evaluate 250 and 350 mg/m2 IV Kevetrin thrice weekly for 3 weeks in about 10 patients....